Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)

Inclusion Criteria: * Adults over 20 years old * Acute cerebral infarction within 30 days of symptom onset was confirmed by diffusion-weighted brain magnetic resonance imaging (DWI) * Cancer-related stroke, not diagnosed with other classic (arteriosclerosis, cardioembolicm, small-vessel occlusion, etc.) cerebral infarction, within six months of diagnosis, chemotherapy, surgery for cancer. * with informed consent from the patient or next-of-kin, When the subject becomes able to decide whether to participate in the study, the researcher acquires further consent directly from the subject. Exclusion Criteria: * Patients with primary intracranial malignancy * Patients with classic causes of cerebral infarction * Patients with infectious or immunological disease that may affect blood D-dimer levels * Patients whose cerebral infarction is thought to be caused by tumor (vascular occlusion due to tumor tissue) * Patients who can not use anticoagulants with thrombocytopenia (platelet \<50,000), anemia (hemoglobin \<8) * Decreased renal function (creatine clearance \<15 mL / mim) * Patients who received intravenous tissue plasminogen activator * Patients with uncontrolled severe hypertension * Patients who received prosthetic heart valve replacement requiring anticoagulation * Patients with moderate to severe mitral stenosis * Pulmonary embolism requiring hemodynamically unstable or thrombolysis or pulmonary embolization * Pregnant and lactating women * Patients who are hypersensitive to the major component or constituent of the test drug * Patients with liver diseases associated with blood clotting disorders and clinically significant bleeding risks